망막모세포종 시장 – 2024-2031년

Retinoblastoma Market - 2024-2031

상품코드PH6886
발행기관DataM Intelligence
발행일2024.10.22
페이지 수181 Pages
포맷PDF + EXCEL
커버리지Global

₩6,525,000 – ₩11,775,000

보고서 요약(국문)

보고서 개요
전 세계 망막모세포종 시장은 2023년 9억 7,015만 달러에 달했으며, 2024년부터 2031년까지 연평균 5.2%의 성장률을 보이며 2031년에는 14억 4,028만 달러에 이를 것으로 예상됩니다.
망막모세포종은 망막 조직에서 발생하는 매우 드문 소아암입니다. 한쪽 눈 또는 양쪽 눈 모두에 발생할 수 있습니다. 대부분의 망막모세포종은 유전되지 않지만, 일부는 유전됩니다. 따라서 가족력이 있는 어린이는 어릴 때부터 안과 검진을 받는 것이 중요합니다. 망막모세포종은 일반적으로 동공 확장 검사, 검안경 검사, 형광 혈관 조영술, 망막전위도 검사, RB1 유전자 검사, 안구 초음파 검사, 안구 자기공명영상(MRI) 검사, 그리고 경우에 따라 생검 등 다양한 방법을 통해 진단됩니다.
치료법과 조기 진단 기술의 발전으로 망막모세포종의 예후는 크게 개선되었습니다. 그러나 이 질환은 아이의 시력과 전반적인 건강에 장기적인 영향을 미칠 수 있으므로, 장기적인 결과를 관리하고 잠재적인 문제를 해결하기 위해 정기적인 추적 관리가 필요합니다.
시장 동향: 성장 동력
신약 및 치료법에 대한 수요 증가가 시장 성장을 견인합니다.
신약 및 치료법에 대한 수요 증가는 시장 성장을 촉진하는 주요 요인입니다. 최근 몇 년 동안 소아 망막모세포종 발병률 증가로 인해 환자 치료 결과 개선을 위한 혁신적인 약물 및 치료법에 대한 수요가 증가했습니다. 개인 맞춤형 의학은 환자 개개인의 고유한 유전적 프로필과 질병 특성에 따라 치료법을 맞춤화하는 것으로, 망막모세포종을 포함한 종양학 분야에서 중요성을 얻고 있습니다. 망막모세포종 치료를 위한 혁신적인 약물에 대한 수요는 더욱 정확하고 효과적인 치료법을 제공하고 잠재적으로 더 나은 치료 결과를 가져오기 위해 지속적으로 증가하고 있습니다.

예를 들어, 2023년 2월, 알레포손 바이오파마슈티컬스(Alephoson Biopharmaceuticals Ltd.)는 세포 투과 펩타이드가 멜팔란에 공유 결합된 펩타이드-약물 접합체를 공개했는데, 이는 망막모세포종 치료에 유용하다고 알려져 있습니다. 또한, 많은 임상 시험과 연구 활동이 빠르게 진행되어 더 나은 치료법을 위한 혁신적인 발명품들이 많이 나오고 있습니다. 이러한 혁신적인 치료법에는 기술적 발전도 포함되는데, 이러한 발전은 질병과 그 메커니즘에 대한 이해를 높여 환자의 치료 결과를 개선하는 데 도움이 됩니다. 따라서 혁신적인 치료법을 위한 많은 임상 시험과 연구 활동이 활발히 진행되고 있습니다.
제한 요인
치료와 관련된 높은 비용과 같은 요인들이 시장 성장을 저해할 것으로 예상됩니다. 표적 치료법은 임상 시험에서 유망한 결과를 보여주고 있지만, 개발 및 제조 비용이 많이 들 수 있습니다. 이러한 혁신적인 치료법의 연구 개발 비용과 임상 시험 수행 비용을 합하면 약값이 상승하여 망막모세포종 치료를 원하는 환자들의 치료 부담을 가중시킬 수 있습니다.

시장 세분화 분석
망막모세포종 시장은 질병 유형, 적용 분야, 최종 사용자 및 지역별로 세분화됩니다.
유전성 망막모세포종 부문은 망막모세포종 시장 점유율의 약 48.3%를 차지했습니다.
유전성 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 비유전성 망막모세포종은 산발성 망막모세포종이라고도 합니다. 망막모세포종을 앓는 어린이의 약 60%는 비유전성 망막모세포종입니다. 일반적으로 어린이는 RB1 유전자의 정상 복사본 2개를 가지고 태어납니다. 망막모세포에서 RB1 유전자의 두 복사본 모두에 돌연변이가 발생하면 어린이의 눈에 망막모세포종 종양이 형성됩니다. 비유전성 망막모세포종을 앓는 어린이는 한쪽 눈에만 종양이 발생하는데, 이를 단측성 망막모세포종이라고 합니다. 이들은 일반적으로 RB1 돌연변이를 자녀에게 유전시키지 않습니다.

시장 지역 분석
북미는 망막모세포종 시장 점유율의 약 43.5%를 차지했습니다.
북미 지역은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 이 지역의 기술 발전은 시장 성장을 견인하는 요인입니다. 망막모세포종은 희귀 질환이지만, 북미 지역에서는 발병률이 높습니다. 포괄적인 암 치료법과 선진 진단 기술의 발달로 질병의 모니터링, 관리 및 치료가 더욱 효과적으로 이루어지고 있습니다.
미국 국립암연구소(NCI)에 따르면, 미국에서는 매년 200~350명의 어린이가 망막모세포종 진단을 받는 것으로 추정됩니다. 북미, 특히 미국에는 망막모세포종 치료제 및 치료법 개발과 상용화에 적극적으로 참여하는 주요 제약 회사, 의료 기기 제조업체 및 연구 기관이 많이 있습니다. 이 지역의 탄탄한 제약 및 의료 산업은 상당한 투자를 유치하고 망막모세포종 치료법 혁신을 촉진합니다.

시장 세분화
질병 유형별
측면성  
단측성 망막모세포종
양측성 망막모세포종
삼측성 망막모세포종
유전  
유전성 망막모세포종
비유전성 망막모세포종
치료법별
수술  
방사선 치료
냉동 치료
레이저 치료
화학 요법  
사이클로포스파미드
카보플라틴
빈크리스틴
기타
최종 사용자별
병원  
안과  
암 연구 센터  
기타
지역별
북미  
미국  
캐나다  
멕시코  
유럽  
독일  
영국  
프랑스  
스페인  
이탈리아  
기타 유럽   
남미  
브라질  
아르헨티나  
기타 남미   
아시아 태평양  
중국  
인도  
일본  
한국  
기타 아시아 태평양
중동 및 아프리카
시장 경쟁 환경
망막모세포종 시장의 주요 글로벌 기업으로는 Pfizer Inc., Bristol Myers Squibb Company, Teva Pharmaceutical Pvt Ltd., Merck and Co., Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson, Baxter International, Inc., AbbVie Inc., Hikma Pharmaceuticals Plc 등이 있습니다.
주요 개발 사항
2024년 8월, Theriva Biologics Inc.는 소아 망막모세포종 환자 치료제인 VCN-01에 대해 FDA로부터 희귀 소아 질환 치료제 지정을 받았습니다.
2023년 7월, FDA는 망막모세포종을 포함한 다양한 암 치료를 위한 병용 요법에 사용되는 사이클로포스파미드 주사제 200mg/mL 바이알에 대한 신약 허가 신청(NDA)을 승인했습니다. 이번 승인을 통해 제품의 안전성과 효능이 입증되고, 회사는 치료 선택의 폭을 넓힐 수 있을 것으로 기대됩니다.
보고서 ​​구매 이유
질병 유형, 적용 분야, 최종 사용자 및 지역별 망막모세포종 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악하기 위함입니다.
트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴할 수 있습니다.
모든 세그먼트를 포함한 망막모세포종 시장 수준의 다양한 데이터 포인트가 담긴 엑셀 시트가 제공됩니다.
PDF 보고서는 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석 자료입니다.
주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료가 엑셀 파일로 제공됩니다.
망막모세포종 시장 보고서는 약 51개의 표, 54개의 그림, 181페이지 분량입니다.
대상 고객 (2024년 기준)
제조업체/구매자
산업 투자자/투자은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Report Overview
The Global Retinoblastoma Market reached US$ 970.15 million in 2023 and is expected to reach US$ 1440.28 million by 2031, growing at a CAGR of 5.2% during the forecast period 2024-2031.
Retinoblastoma is a very rare childhood cancer that forms in the tissues of the retina. It can occur in one or both eyes. Most cases of retinoblastoma are not inherited, but some are, and children with a family history of the disease should have their eyes checked beginning at an early age. Retinoblastoma is generally diagnosed by various methods like examination of dilated pupils, ophthalmoscopy, fluorescein angiography, electroretinography, RB1 gene test, ultrasound examination of the eye, magnetic resonance imaging of the eye, and biopsy in some cases. 
The outlook for retinoblastoma has improved significantly as therapy and early detection techniques have advanced. However, the condition can have long-term repercussions on a child's vision and overall health, necessitating regular follow-up care to manage long-term outcomes and handle any potential issues.
Market Dynamics: Drivers
Increasing demand for new drugs and treatments drives the market
The increasing demand for new drugs and treatment drives propels the market growth. In recent years, the demand for innovative drugs and treatments has increased for enhanced patient outcomes due to the increasing prevalence of retinoblastoma in children. Personalized medicine involves tailoring treatments to individual patients based on their unique genetic profile and disease characteristics gained prominence in oncology including retinoblastoma. The demand for innovative drugs in retinoblastoma is continuously increasing to provide more precise and effective therapies, potentially leading to better treatment outcomes. 
For instance, in February 2023, Alephoson Biopharmaceuticals Ltd. disclosed peptide-drug conjugates comprising a cell-penetrating peptide covalently linked to melphalan that is reported to be useful for the treatment of retinoblastoma. Moreover, many clinical trials and research activities are going on rapidly, leading to many innovative inventions for better treatment. The innovative treatment options also include technological advancements, these advancements help in a better understanding of the disease and its mechanisms resulting in better and enhanced patient outcomes. Hence, many clinical trials and research activities are being performed for innovative treatment options.
Restraints
Factors such as high costs associated with the treatment is expected to hamper the market. The targeted therapies are showing promising results in clinical trials, but they can be costly to develop and manufacture. The research and development costs for these innovative treatments, coupled with the expenses of conducting clinical trials, may lead to higher prices for these drugs, impacting their affordability for patients seeking retinoblastoma treatment. 
Market Segment Analysis
The retinoblastoma market is segmented based on disease type, application, end-user, and region.
The segment inheritance retinoblastoma accounted for approximately 48.3% of the retinoblastoma market share
The inheritance segment is expected to hold the largest market share over the forecast period. The non-hereditary retinoblastoma is also known as sporadic retinoblastoma. About 60% of children with retinoblastoma have non-hereditary retinoblastoma. Commonly, children are born with 2 normal copies of the RB1 gene. A mutation of both copies of the RB1 gene in a retinoblast causes a retinoblastoma tumor to form in the eyes of the children. Children with non-hereditary retinoblastoma only develop a tumor in one eye known as unilateral retinoblastoma. They will not usually pass the RB1 mutation on to their future children. 
Market Geographical Analysis
North America accounted for approximately 43.5% of the retinoblastoma market share 
North America region is expected to hold the largest market share over the forecast period. The technological advancements in this region, help to propel the market. Though retinoblastoma is a rare disease, there is a high prevalence of this type of cancer in North America. The availability of comprehensive cancer treatments and advanced diagnostic capabilities allows for better disease monitoring, management, and treatment. 
According to the National Cancer Institute, there are 200 to 350 children in the United States who are estimated to be diagnosed annually with the disease. North America, especially the United States is home to several major pharmaceutical companies, medical device manufacturers, and research institutions that are actively involved in the development and commercialization of retinoblastoma drugs and treatments. The region's established pharmaceutical and healthcare sectors attract significant investments and foster innovations in retinoblastoma treatments.
Market Segmentation
By Disease Type
Laterality  
Unilateral Retinoblastoma
Bilateral Retinoblastoma
Trilateral Retinoblastoma
Inheritance 
Hereditary Retinoblastoma
Non-Hereditary Retinoblastoma
By Treatment
Surgery 
Radiation Therapy
Cryotherapy
Laser Therapy
Chemotherapy 
Cyclophosphamide
Carboplatin
Vincristine
Others
By End-User
Hospitals
Ophthalmic Clinics 
Cancer Research Centers
Others
By Region
North America 
U.S.
Canada
Mexico 
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe 
South America
Brazil
Argentina
Rest of South America 
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the retinoblastoma market include Pfizer Inc., Bristol Myers Squibb Company, Teva Pharmaceutical Pvt Ltd., Merck and Co., Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson, Baxter International, Inc., AbbVie Inc., and Hikma Pharmaceuticals Plc among others.
Key Developments
In August 2024, Theriva Biologics Inc. received an FDA-granted rare pediatric drug designation for VCN-01 as a treatment for pediatric patients with retinoblastoma.
In July 2023, the FDA approved a new drug application (NDA) for 200-mg/mL vials of cyclophosphamide injection for use in combination therapy for the treatment of various cancers including retinoblastoma. The approval is expected to demonstrate the safety and efficacy of the product and help the company broaden the available treatment options.
Why Purchase the Report?
To visualize the retinoblastoma market segmentation based on disease type, application, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of retinoblastoma market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The retinoblastoma market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Treatment
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Demand for New Drugs and Treatment Drives the Market
4.1.2. Restraints
4.1.2.1. High Cost Associated with the Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Disease Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
6.1.2. Market Attractiveness Index, By Disease Type
6.2. Laterality *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Inheritance
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Surgery*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Radiation Therapy
7.4. Cryotherapy
7.5. Laser Therapy
7.6. Chemotherapy
7.7. Others
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ophthalmic Clinics
8.4. Cancer Research Centers
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Pfizer Inc. *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Bristol Myers Squibb Company
11.3. Teva Pharmaceutical Pvt. Ltd.
11.4. Merck and Co.
11.5. Novartis AG
11.6. GlaxoSmithKline Plc
11.7. Johnson & Johnson
11.8. Baxter International Inc.
11.9. AbbVie Inc.
11.10. Hikma Pharmaceuticals Plc (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4. Key Developments, Bristol Myers Squibb Company, Teva Pharmaceutical Pvt. Ltd., Merck and Co., Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson, Baxter International Inc., AbbVie Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Retinoblastoma Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Retinoblastoma Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Retinoblastoma Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Retinoblastoma Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Retinoblastoma Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Retinoblastoma Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 7 Global Retinoblastoma Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Retinoblastoma Market Value, By Treatment, 2022-2031 (US$ Million)

Table 9 Global Retinoblastoma Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Retinoblastoma Market Value, By End-User, 2022-2031 (US$ Million)

Table 11 Global Retinoblastoma Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Retinoblastoma Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Retinoblastoma Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 14 North America Retinoblastoma Market Value, By Treatment, 2022-2031 (US$ Million)

Table 15 North America Retinoblastoma Market Value, By End-User, 2022-2031 (US$ Million)

Table 16 North America Retinoblastoma Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Retinoblastoma Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 18 South America Retinoblastoma Market Value, By Treatment, 2022-2031 (US$ Million)

Table 19 South America Retinoblastoma Market Value, By End-User, 2022-2031 (US$ Million)

Table 20 South America Retinoblastoma Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Retinoblastoma Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 22 Europe Retinoblastoma Market Value, By Treatment, 2022-2031 (US$ Million)

Table 23 Europe Retinoblastoma Market Value, By End-User, 2022-2031 (US$ Million)

Table 24 Europe Retinoblastoma Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Retinoblastoma Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Retinoblastoma Market Value, By Treatment, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Retinoblastoma Market Value, By End-User, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Retinoblastoma Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East and Africa Retinoblastoma Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 30 Middle East and Africa Retinoblastoma Market Value, By Treatment, 2022-2031 (US$ Million)

Table 31 Middle East and Africa Retinoblastoma Market Value, By End-User, 2022-2031 (US$ Million)

Table 32 Middle East and Africa Retinoblastoma Market Value, By Country, 2022-2031 (US$ Million)

Table 33 Pfizer Inc.: Overview

Table 34 Pfizer Inc.: Product Portfolio

Table 35 Pfizer Inc.: Key Developments

Table 36 Bristol Myers Squibb Company: Overview

Table 37 Bristol Myers Squibb Company: Product Portfolio

Table 38 Bristol Myers Squibb Company: Key Developments

Table 39 Teva Pharmaceutical Pvt Ltd: Overview

Table 40 Teva Pharmaceutical Pvt Ltd: Product Portfolio

Table 41 Teva Pharmaceutical Pvt Ltd: Key Developments

Table 42 Merck and Co.: Overview

Table 43 Merck and Co.: Product Portfolio

Table 44 Merck and Co.: Key Developments

Table 45 Novartis AG: Overview

Table 46 Novartis AG: Product Portfolio

Table 47 Novartis AG: Key Developments

Table 48 GlaxoSmithKline Plc: Overview

Table 49 GlaxoSmithKline Plc: Product Portfolio

Table 50 GlaxoSmithKline Plc: Key Developments

Table 51 Johnson & Johnson: Overview

Table 52 Johnson & Johnson: Product Portfolio

Table 53 Johnson & Johnson: Key Developments

Table 54 Baxter International Inc.: Overview

Table 55 Baxter International Inc.: Product Portfolio

Table 56 Baxter International Inc.: Key Developments

Table 57 AbbVie Inc.: Overview

Table 58 AbbVie Inc.: Product Portfolio

Table 59 AbbVie Inc.: Key Developments

Table 60 Hikma Pharmaceuticals Plc: Overview

Table 61 Hikma Pharmaceuticals Plc: Product Portfolio

Table 62 Hikma Pharmaceuticals Plc: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 2 Global Retinoblastoma Market Share, By Disease Type, 2023 & 2031 (%)

Figure 3 Global Retinoblastoma Market Share, By Treatment, 2023 & 2031 (%)

Figure 4 Global Retinoblastoma Market Share, By End-User, 2023 & 2031 (%)

Figure 5 Global Retinoblastoma Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Retinoblastoma Market Y-o-Y Growth, By Disease Type, 2023-2031 (%)

Figure 7 Laterality Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 8 Inheritance Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 9 Global Retinoblastoma Market Y-o-Y Growth, By Treatment, 2023-2031 (%)

Figure 10 Surgery Treatment in Global Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 11 Radiation Therapy Treatment in Global Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 12 Cryotherapy Treatment in Global Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 13 Laser Therapy Treatment in Global Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 14 Chemotherapy Treatment in Global Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 15 Others Treatment in Global Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 16 Global Retinoblastoma Market Y-o-Y Growth, By End-User, 2023-2031 (%)

Figure 17 Hospitals End-User in Global Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 18 Ophthalmic Clinics End-User in Global Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 19 Cancer Research Centers End-User in Global Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 20 Others End-User in Global Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 21 Global Retinoblastoma Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 22 North America Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 23 North America Retinoblastoma Market Share, By Disease Type, 2023 & 2031 (%)

Figure 24 North America Retinoblastoma Market Share, By Treatment, 2023 & 2031 (%)

Figure 25 North America Retinoblastoma Market Share, By End-User, 2023 & 2031 (%)

Figure 26 North America Retinoblastoma Market Share, By Country, 2023 & 2031 (%)

Figure 27 South America Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 28 South America Retinoblastoma Market Share, By Disease Type, 2023 & 2031 (%)

Figure 29 South America Retinoblastoma Market Share, By Treatment, 2023 & 2031 (%)

Figure 30 South America Retinoblastoma Market Share, By End-User, 2023 & 2031 (%)

Figure 31 South America Retinoblastoma Market Share, By Country, 2023 & 2031 (%)

Figure 32 Europe Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 33 Europe Retinoblastoma Market Share, By Disease Type, 2023 & 2031 (%)

Figure 34 Europe Retinoblastoma Market Share, By Treatment, 2023 & 2031 (%)

Figure 35 Europe Retinoblastoma Market Share, By End-User, 2023 & 2031 (%)

Figure 36 Europe Retinoblastoma Market Share, By Country, 2023 & 2031 (%)

Figure 37 Asia-Pacific Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 38 Asia-Pacific Retinoblastoma Market Share, By Disease Type, 2023 & 2031 (%)

Figure 39 Asia-Pacific Retinoblastoma Market Share, By Treatment, 2023 & 2031 (%)

Figure 40 Asia-Pacific Retinoblastoma Market Share, By End-User, 2023 & 2031 (%)

Figure 41 Asia-Pacific Retinoblastoma Market Share, By Country, 2023 & 2031 (%)

Figure 42 Middle East and Africa Retinoblastoma Market Value, 2022-2031 (US$ Million)

Figure 43 Middle East and Africa Retinoblastoma Market Share, By Disease Type, 2023 & 2031 (%)

Figure 44 Middle East and Africa Retinoblastoma Market Share, By Treatment, 2023 & 2031 (%)

Figure 45 Middle East and Africa Retinoblastoma Market Share, By End-User, 2023 & 2031 (%)

Figure 46 Pfizer Inc.: Financials

Figure 47 Bristol Myers Squibb Company: Financials

Figure 48 Teva Pharmaceutical Pvt Ltd: Financials

Figure 49 Merck and Co.: Financials

Figure 50 Novartis AG: Financials

Figure 51 GlaxoSmithKline Plc: Financials

Figure 52 Johnson & Johnson: Financials

Figure 53 Baxter International Inc.: Financials

Figure 54 AbbVie Inc.: Financials

Figure 55 Hikma Pharmaceuticals Plc: Financials